- Home
- SM vs CNTA Comparison
SM vs CNTA Comparison
Compare SM & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SM | CNTA |
|---|---|---|
| Founded | 1908 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.1B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SM | CNTA |
|---|---|---|
| Price | $31.46 | $39.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $34.36 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 4.0M | 2.0M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,154,000,000.00 | $15,000,000.00 |
| Revenue This Year | $129.01 | N/A |
| Revenue Next Year | $6.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.24 | N/A |
| 52 Week Low | $17.45 | $10.95 |
| 52 Week High | $33.25 | $40.26 |
Technical Indicators
Market Signals| Indicator | SM | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 72.11 |
| Support Level | $25.18 | $39.36 |
| Resistance Level | $31.50 | $39.86 |
| Average True Range (ATR) | 1.18 | 0.15 |
| MACD | 0.04 | -0.39 |
| Stochastic Oscillator | 96.24 | 47.52 |
Price Performance
Historical ComparisonAbout SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.